A recombinant VSV-vectored vaccine rapidly protects nonhuman primates against lethal Nipah virus disease.
Stephanie L Foster, Courtney Woolsey, Viktoriya Borisevich, Krystle N Agans, Abhishek N Prasad, Daniel J Deer, Joan B Geisbert, Natalie S Dobias, Karla A Fenton, Robert W Cross, Thomas W Geisbert
Author Information
Stephanie L Foster: Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX 77555-0610. ORCID
Courtney Woolsey: Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX 77555-0610. ORCID
Viktoriya Borisevich: Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX 77555-0610.
Krystle N Agans: Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX 77555-0610. ORCID
Abhishek N Prasad: Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX 77555-0610. ORCID
Daniel J Deer: Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX 77555-0610.
Joan B Geisbert: Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX 77555-0610.
Natalie S Dobias: Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX 77555-0610.
Karla A Fenton: Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX 77555-0610. ORCID
Robert W Cross: Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX 77555-0610. ORCID
Thomas W Geisbert: Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX 77555-0610. ORCID
SignificanceConcern has increased about the pandemic potential of Nipah virus (NiV). Similar to SARS-CoV-2, NiV is an RNA virus that is transmitted by respiratory droplets. There are currently no NiV vaccines licensed for human use. While several preventive vaccines have shown promise in protecting animals against lethal NiV disease, most studies have assessed protection 1 mo after vaccination. However, in order to contain and control outbreaks, vaccines that can rapidly confer protection in days rather than months are needed. Here, we show that a recombinant vesicular stomatitis virus vector expressing the NiV glycoprotein can completely protect monkeys vaccinated 7 d prior to NiV exposure and 67% of animals vaccinated 3 d before NiV challenge.
